Frontier Medicines Corporation
151 Oyster Point Blvd.
South San Francisco
10 articles with Frontier Medicines Corporation
11/19/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
7/21/2021More money means more progress for potentially life-saving therapies. Here's a peek at some biopharma companies adding to their books this week.
Frontier Medicines will support the continued development of the company’s chemoproteomics drug discovery program, including lead asset, an inhibitor of KRASG12C.
Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, announced the closing of an $88.5 million Series B financing round.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Therapies developed using E3 ligase proteins will get a potent infusion, as AbbVie combines its commercialization expertise with Frontier Medicine’s proprietary chemoproteomics platform to develop potentially efficacious therapies for difficult-to-drug protein targets.
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
Frontier Medicines Announces Three Executive Hires: Chief Scientific Officer, Chief Technology Officer & Head of Degrader Technologies
South San Francisco-based Frontier Medicines today announced three key additions to its executive team with the hiring of Chief Scientific Officer Kevin Webster, Chief Technology Officer Johannes Hermann and Head of Degrader Technologies James Winkler.
Frontier Medicines Launches with $67 Million to Develop Novel Medicines that Drug the “Undruggable” Targets Driving Human Disease
Frontier Medicines today announced the closing of a Series A Preferred Stock financing round of $67 million led by Deerfield Management, Droia Oncology Ventures and MPM Capital, with participation from DCVC Bio (an affiliated fund of DCVC), RA Capital Management and other investors.